Skip to main content
. 2017 Dec 20;7(4):e1409322. doi: 10.1080/2162402X.2017.1409322

Figure 2.

Figure 2.

Treatment induces maturation of the immature NK cell population. (A) Analysis of NK cell subpopulations based on level of CD56 and CD16 expression that divides NK cells in 4 subpopulations: CD56brCD16− (top, left panel), CD56brCD16+ (top, right panel), CD56dimCD16− (bottom, left panel) and CD56dimCD16+ (bottom, right panel). (B) Assessment of NK cell maturation status determined by expression of the maturation markers CD161, CD62 L and CD57. (C) Expression of several KIR receptors on healthy donor and patient NK cells: CD158 a (KIR2DL1), CD158b (KIR2DL2/3) and CD158e (KIR3DL1). (D) Expression of the inhibitory heterodimer complex NKG2 A/CD94 and the activating receptor NKG2D. Patient: n = 16, healthy donor: n = 4. Significance was determined by paired t-test between day 0 versus following time-points, and one-way ANOVA between HD and patients at every time-points with * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001.